Indivior Pharmaceuticals Inc
INDVNASDAQStock · Data from SEC EDGAR 13F · Held by 7 of 87 tracked investors
Indivior Pharmaceuticals Inc at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation90
- Growth78
- Profitability93
- Quality25
- Debt67
- Stability72
- ✓Out of 100 USD of revenue, 27 USD is left as net profit.
- ✓Revenue grew 11.2% a year over 3 years.
- ✓The stock is cheaper: you pay 12.3 USD for 1 USD of annual earnings.
- ✓The analysts' average target is 41% above the price.
- Nothing notable from the statements.
The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.
Is the stock expensive?
Fairly cheapFor 1 USD of annual earnings you pay 12.3 USD. Based on next year's estimates 7.1 USD.
- P/E
- 12.3×
- P/S
- 3.1×
- EV/EBITDA
- 7.6×
Is the company growing?
GrowingRevenue over 3 years grew 11.2% a year. Last year 13.6%.
Does it make money?
ExcellentEarnings results
| Quarter | Reported | EPS | Analyst estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | 3 Aug 2026 | 1.15 | 0.97 | +18.6% |
| Mar 2026 | 30 Apr 2026 | 0.96 | 0.64 | +50% |
| Dec 2025 | 26 Feb 2026 | 0.82 | 0.65 | +26.2% |
| Sep 2025 | 30 Oct 2025 | 0.72 | 0.38 | +89.5% |
EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.
Chart INDV
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
7HM Howard Marks Oaktree Capital Management | 3.49% |
SC Steven Cohen Point72 Asset Management | 0.06% |
IE Israel Englander Millennium Management | 0.03% |
RD Ray Dalio Bridgewater Associates | 0.01% |
JG Joel Greenblatt Gotham Asset Management | 0.01% |
KG Ken Griffin Citadel Advisors | 0.01% |
Šn Švýcarská národní banka Swiss National Bank | 0% |
Frequently asked questions
How much is Indivior Pharmaceuticals Inc (INDV) stock?
Indivior Pharmaceuticals Inc shares trade at $34.72, +0.46% over the last trading day. The price is delayed.
What is the market cap of Indivior Pharmaceuticals Inc?
The market cap of Indivior Pharmaceuticals Inc is about $4.1B and its price-to-earnings ratio (P/E) is 12.3.
Which big investors hold Indivior Pharmaceuticals Inc?
According to the latest 13F filings, 7 of 87 tracked investors hold Indivior Pharmaceuticals Inc, for example Howard Marks, Steven Cohen, Israel Englander.
When will Indivior Pharmaceuticals Inc report its next results?
The next earnings report of Indivior Pharmaceuticals Inc is expected on 29 Oct 2026.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.